To confirm the safety and efficacy of Z-213 until 12 weeks after start of Z-213 administration in patients with iron deficiency Anemia
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
39
The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
Unnamed facility
Tokyo, Japan
Number of participants with Adverse Drug Reactions
Time frame: 12 weeks
Number of participants with Adverse Events
Time frame: 12 weeks
Maximum change in Hb value
Time frame: 12 weeks
Change in Hb value
Time frame: 12 weeks
Proportion of responders
Time frame: 12 weeks
Proportion of subjects with normalization in Hb value
Time frame: 12 weeks
Proportion of cumulative dosage
Time frame: 12 weeks
Number of doses to total dose achieved
Time frame: 12 weeks
Time to total dose achieved
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.